Phase 2 N=399 N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
Radiocontrast Nephropathy
Primary: Number of Participants With Contrast-induced Nephropathy — 14; 12 Participants — p=>0.5
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
N/A N=28 Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
Phase 4 N=122 Contrast Nephropathy and Nitrates
Contrast Induced Nephropathy
Primary: Change in GFR — 1.8; -4.1 mL/min
Phase 4 N=60 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
Proteinuria · Idiopathic Membranous Nephropathy
Primary: Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 Weeks — 1; 5; 2; 0 Participants
Phase 4 N=21 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI — 22.04 1/ms
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Phase 4 N=1,302 Study of Adacel® Vaccine Administered to Persons 10 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine — 30.1; 32.0; 232; 225 Titers (1/dilutions)
Phase 4 N=59 Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection
Emergent Coronary Procedure
Primary: Occurrence of Contrast-induced Nephropathy — 1; 8 participants
Phase 3 N=301 Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy
Renal Failure
Primary: Contrast-induced Nephropathy — 6.1; 6.0 percentage of contrast nephropaty
Phase 2 N=35 Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients
Breast Cancer
Primary: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients — 2.6; 3.4 units on a scale — p=0.0077
Phase 4 N=1,330 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants With Diphtheria and Tetanus Seroprotection — 100.0; 100.0; 99.8; 99.4 Percentage of participants
Phase 2 N=83 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Phase 2 N=9 Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
Lupus Membranous Nephropathy
Primary: Percent Change in Urine Protein From Baseline (Day 1) to Week 16 — -2.8; -51.2 percent change
Phase 1 N=6 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants